Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

NCT05085548 is registered in ClinicalTrials.gov with ProDa BioTech, LLC as lead sponsor.

NCT NCT05085548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05085548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
Lead sponsor
ProDa BioTech, LLC
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2021
Completion date
April 10, 2026
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer, solid tumor malignancies